A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativa

Journal:

Journal of the American Academy of Dermatology

Published:

2025-10-07

DOI:

10.1016/j.jaad.2025.10.015

Affiliations:

6

Authors:

10

Go to article

Institutions	Authors	Share
Lilly, United States of America (USA)	6.000000	0.60
Beth Israel Deaconess Medical Center (BIDMC), United States of America (USA)	1.000000	0.10
First OC Dermatology, United States of America (USA)	1.000000	0.10
CenExel Clinical Research, United States of America (USA)	1.000000	0.10
Duke University Health System, United States of America (USA)	1.000000	0.10

Interested in Clinical Sciences?